This scientific study aimed to evaluate the effect of polymorphisms in the APEX1 (rs2307486) on the effectiveness of hypouricemic therapy in women with gout. The study included 102 female and 100 male patients diagnosed with gout in 2021–2025. The patients were prescribed allopurinol and febuxostat, and their effectiveness was assessed across different genotypes of the above genes. According to the results of the study, patients with the G/G genotype of the APEX1 gene had a low response to allopurinol, and only febuxostat was effective. In patients with the T/T genotype, both drugs were almost equally effective. These results indicate that polymorphisms of the APEX1 gene are important pharmacogenetic biomarkers in determining the individual effectiveness of hypouricemic therapy. The selection of drugs and their doses based on a personalized approach increases therapeutic efficacy, eliminates resistance, and improves quality of life.

Keywords: gout, women, hypouricemic therapy, APEX1, gene polymorphism, pharmacogenetics, febuxostat, allopurinol, genotype, personalized medicine, quality of life.